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Background
Cancer vaccines aim at inducing tumour-specific immune
responses. However, in clinical studies so far these
approaches have limited antitumour effect. Evidence is
accumulating that MDSC (myeloid-derived suppressor
cells) can suppress the antitumour immune response.
Reversal of MDSC-mediated immune suppression by
treatment with the tyrosine kinase inhibitor sunitinb can
therefore possibly increase the efficacy of cancer vaccines.
Material and methods
We developed a method to assess MDSC depletion in a
preclinical model of HPV-induced neoplasia. TC-1 (cells
expressing HPV16-E7) tumour-bearing mice were injected
with different dosages of sunitinib daily, for 9 days, with
and without immunisation with SFVeE6,7 (Semliki Forest
virus encoding human papilloma virus E6,7 tumor anti-
gens). Intra-tumoral, intra-splenic and circulating MDSC
and CD8 T cell levels were assessed after treatment.
Results
Upon sunitinib treatment, the absolute numbers of intra-
tumoral, intra-splenic and circulating MDSC decreased in
a dose-dependent manner. Combined sunitinib and
immunisation therapy led to a marked decrease of intra-
tumoral, intra-splenic and circulating MDSC levels as
compared to non-treated control or immunisation alone.
The bi-therapy regimen markedly enhanced intra-tumoral,
intra-splenic and circulating levels of CD8 T cells. The
highest number of circulating CD8 T cells undergoing
degranulation (CD107ab+) was observed after combined
treatment. Most importantly, this combined sunitinib and
immunisation treatment regimen abrogated tumour
growth.
Conclusions
In summary, we demonstrated that sunitinib alone or in
combination with immunisation can decrease intra-
tumoral, intra-splenic and circulating MDSC levels. Also,
combination of sunitinib treatment with immunisation
enhanced levels and degranulating activity of CD8 T cells,
thus resulting in reversal of tumour growth. This study
indicates that SFV-based immunotherapy combined with
sunitinib treatment could improve treatment outcome.
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